How Patient-Centric Strategies Help Pharma Companies Bring their Drugs to Market Faster

At Agilisium, we believe innovation is essential for advancements in diagnostics, therapeutics, and digital health, with patient-centric clinical trials playing a crucial role in accelerating this journey and ensuring real-world impact.

Bringing cutting-edge diagnostics and therapeutics from discovery to delivery demands more than just scientific excellence; it requires a collaborative ecosystem. Agilisium drives collaboration by harnessing data and delivering actionable insights, effectively bridging the gap between scientific breakthroughs and real-world patient impact.  

Recruitment, Engagement and Patient-Centricity

Despite spending nearly $1.9 billion a year on recruitment, around four in five clinical trials fail to recruit or retain sufficient individuals. Many trials don’t include a sufficiently diverse group of people, meaning that the trials that are completed may not accurately reflect the actual patient population. This can increase the time taken to get a drug to market, delay patient access, limit the audience for the drug and reduce the company’s opportunity for a return on investment.

Recruitment and retention challenges include:

• Lack of public awareness of the studies and their importance.

• Anxiety about involvement.

• Competition for trial participants in rare diseases, or in fields where there is a lot of active drug development.

• Unwillingness of ethnically diverse populations

• Difficulties accessing clinical trial sites for older people or people with concomitant conditions, including lack of public transport.

• Burden of frequent site visits or inconvenient appointment times for people in work or education, or who have caring responsibilities.

• Strict trial inclusion/exclusion criteria that exclude parts of the patient population.  

Patient-centricity has become a buzzword in clinical research and drug development, but it can be a real benefit by improving patient recruitment and retention, as well as patient satisfaction. The patient-centricity and accessibility of a clinical trial can be improved by engaging patient groups and listening to patients’ voices at the clinical trial design and execution stage, to find out what patients actually want and need.  AI can play an important role in improving recruitment, engagement and retention by using patient profiling to find the right patients across the right populations. Data-driven site selection that includes criteria such as site location and accessibility is also important in study design.  

Where access and burden of visits is a barrier, remote patient monitoring and decentralized or hybrid clinical study designs can help. By leveraging wearable technology and AI, not only can the approach cut the number of site visits, but it could also increase the quality of the data produced by allowing real-time health tracking.  

Site Engagement and Enablement

Effective and efficient drug development needs sites that have access to targeted patient populations, and that can work with new technologies and complex protocols, but these can be challenging to find. Creating long-term and collaborative relationships between sponsors and site teams can reduce the burden on sites. Putting in place technology solutions such as clinical trial management systems (CTMS) can further lower the challenges for sites by using tailored workflows and real-time trial management solutions.  

Clinical Data Strategy and Analytics

Clinical trials generate vast amounts of data, and this can end up in silos, or can simply overwhelm data analytics teams. Data also needs to comply with Good Manufacturing Practices (GMP), Good Clinical Practices (GCP) and Good Laboratory Practices (GLP). Integrating clinical data, along with the use of automated tools to verify and validate the information, will ease the pressure, improve data accuracy and quality, and support the route to regulatory approval.  

To maintain trust, patients in clinical trials need to be reassured that their data and personal information remains private and secure. Data security is also important for companies to safeguard their R&D to retain their competitive edge, and to avoid unauthorized generics and counterfeit drugs reaching the market. End-to-end data protection safeguards both patients and drug developers, and ensures regulatory compliance, smoothing market access.  

Clinical Supply and Logistics

A cost-efficient, streamlined and effective clinical trial needs the right drug to be in the right place and the right time, especially where there are time pressures on trial completion, or clinical study sites are spread across the world. This becomes even more critical if the drugs need to be kept at specific temperatures or only have a short shelf life, such as cell- and gene-based therapies. Focusing on manufacturing design, for example scalable, compliant production processes, and on efficient and predictable logistics, improves the chance of clinical trial success.

Accelerate Patient-Centered Innovation with Agilisium

Patient-centric strategies are no longer just an aspiration—they are a necessity for driving meaningful advancements in drug development and improving patient outcomes. By prioritizing patient engagement, leveraging AI-driven insights, and streamlining clinical trial processes, pharma companies can overcome recruitment challenges, enhance data integrity, and expedite regulatory approvals.

At Agilisium, we bring together deep life sciences expertise, intelligent automation, and advanced analytics to bridge the gap between scientific breakthroughs and real-world patient impact. Our solutions enable pharmaceutical organizations to optimize trial efficiency, ensure data security, and accelerate market access—ultimately delivering life-changing therapies to patients faster.

Partner with Agilisium to transform your clinical trial strategy and unlock the full potential of patient-centric innovation.